Sign Up to like & get
recommendations!
1
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz413.047
Abstract: Abstract Background Resistance on the 1st or 2nd generation TKIs in patients with EGFR mutated NSCLC to the therapy occurs on average after 8-12 months. The most common (49-60%) resistance mechanism is the appearance of…
read more here.
Keywords:
pfs;
ctdna;
osimertinib therapy;
therapy ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2022 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/10781552211073823
Abstract: Introduction Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR) used for the treatment of non-small cell lung cancer (NSCLC) presenting an EGFR mutation. Although Osimertinib has a better safety…
read more here.
Keywords:
prolongation;
failure;
patient;
heart ... See more keywords